These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2018048)

  • 1. Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4.
    Daar ES; Ho DD
    Am J Med; 1991 Apr; 90(4A):22S-26S. PubMed ID: 2018048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
    Daar ES; Li XL; Moudgil T; Ho DD
    Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6574-8. PubMed ID: 2395859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.
    Orloff SL; Kennedy MS; Belperron AA; Maddon PJ; McDougal JS
    J Virol; 1993 Mar; 67(3):1461-71. PubMed ID: 8437224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.
    Dey B; Del Castillo CS; Berger EA
    J Virol; 2003 Mar; 77(5):2859-65. PubMed ID: 12584309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor.
    Brighty DW; Rosenberg M; Chen IS; Ivey-Hoyle M
    Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7802-5. PubMed ID: 1909031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary HIV-1 isolates refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin.
    Kennedy PE; Moss B; Berger EA
    Virology; 1993 Jan; 192(1):375-9. PubMed ID: 8517027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120.
    Turner S; Tizard R; DeMarinis J; Pepinsky RB; Zullo J; Schooley R; Fisher R
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1335-9. PubMed ID: 1741386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naturally occurring soluble CD4 in patients with human immunodeficiency virus infection.
    Peakman M; Senaldi G; Foote N; McManus TJ; Vergani D
    J Infect Dis; 1992 May; 165(5):799-804. PubMed ID: 1349032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4 peptide-protein conjugates, but not recombinant human CD4, bind to recombinant gp120 from the human immunodeficiency virus in the presence of serum from AIDS patients.
    Ghetie V; Slaughter C; Wheeler HT; Uhr JW; Vitetta ES
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5690-3. PubMed ID: 2062847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker.
    Beaumont T; Quakkelaar E; van Nuenen A; Pantophlet R; Schuitemaker H
    J Virol; 2004 Jun; 78(11):5651-7. PubMed ID: 15140962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1.
    Hwang SS; Boyle TJ; Lyerly HK; Cullen BR
    Science; 1992 Jul; 257(5069):535-7. PubMed ID: 1636088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial.
    Schooley RT; Merigan TC; Gaut P; Hirsch MS; Holodniy M; Flynn T; Liu S; Byington RE; Henochowicz S; Gubish E
    Ann Intern Med; 1990 Feb; 112(4):247-53. PubMed ID: 2297203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection.
    Husson RN; Chung Y; Mordenti J; Butler KM; Chen S; Duliege AM; Brouwers P; Jarosinski P; Mueller BU; Ammann A
    J Pediatr; 1992 Oct; 121(4):627-33. PubMed ID: 1357124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticles presenting clusters of CD4 expose a universal vulnerability of HIV-1 by mimicking target cells.
    Hoffmann MAG; Bar-On Y; Yang Z; Gristick HB; Gnanapragasam PNP; Vielmetter J; Nussenzweig MC; Bjorkman PJ
    Proc Natl Acad Sci U S A; 2020 Aug; 117(31):18719-18728. PubMed ID: 32690692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.
    Kahn JO; Allan JD; Hodges TL; Kaplan LD; Arri CJ; Fitch HF; Izu AE; Mordenti J; Sherwin JE; Groopman JE
    Ann Intern Med; 1990 Feb; 112(4):254-61. PubMed ID: 2297204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human erythrocytes bearing electroinserted CD4 neutralize infection in vitro by primary isolates of human immunodeficiency virus type 1.
    Tosi PF; Schwartz D; Sharma U; Mouneimne Y; Hannig J; Li G; McKinley G; Grieco M; Flexner CW; Lazarte J; Norse D; Nicolau C; Volsky DJ
    Blood; 1996 Jun; 87(11):4839-44. PubMed ID: 8639857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of AIDS with combinations of antiretroviral agents: a summary.
    Groopman JE
    Am J Med; 1991 Apr; 90(4A):27S-30S. PubMed ID: 2018049
    [No Abstract]   [Full Text] [Related]  

  • 19. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
    Pugach P; Kuhmann SE; Taylor J; Marozsan AJ; Snyder A; Ketas T; Wolinsky SM; Korber BT; Moore JP
    Virology; 2004 Mar; 321(1):8-22. PubMed ID: 15033560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia.
    Schacker T; Coombs RW; Collier AC; Zeh JE; Fox I; Alam J; Nelson K; Eggert E; Corey L
    J Infect Dis; 1994 Jan; 169(1):37-40. PubMed ID: 8277195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.